| Name | Title | Contact Details |
|---|
Foothills Sports Medicine Physical Therapy has convenient locations across Arizona, extended hours to fit your schedule, and accepts most insurance plans. Come experience our hands-on philosophy and individualized treatment approach. Schedule an appoin...
Baystate Health is an integrated health care delivery system serving a population of nearly one million people in western Massachusetts. We are one of the largest health systems in New England with more than 12,000 employees, four hospitals, and over 80 medical practices. Baystate Medical Center has the only Level 1 Trauma Center in the region, and the only neonatal and pediatric intensive care units. University of Massachusetts Medical School-Baystate is the only regional campus of the University of Massachusetts Medical School. Baystate Medical Center has been ranked as one of the nation`s top hospitals for 2015-2016 by U.S. News & World Report and for the third time, Baystate Medical Center has been named a Magnet™ hospital for excellence in nursing services.
The Mason City Clinic was formed on January 1, 1989, with the merger of three physician groups -- Surgical Associates, Internal Medicine Associates and Independent Medical Surgical Group.
ProHEALTH is a dynamic and growing healthcare organization, offering a wide range of employment opportunities. As we continue to grow we continually seek qualified, professional, dedicated individuals to join our team. As the largest private
Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic